Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
A phase 2 trial of Temozolomide, Silevertinib in brain and spinal cord tumours, run by Black Diamond Therapeutics, Inc., now recruiting.
Overview
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII is a phase 2 interventional study registered as NCT07326566 by Black Diamond Therapeutics, Inc., with 162 participants planned, started 2026-05-05 and due to reach its primary completion in 2028-11. Interventions recorded: silevertinib in combination with temozolomide, temozolomide (TMZ). Conditions listed: Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Shares Silevertinib, Black Diamond Therapeutics.
- TrialA Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Shares Brain and spinal cord tumours (all types), Temozolomide.
- CancerPrimary CNS lymphoma
Shares Brain and spinal cord tumours (all types), Temozolomide.